Evidence map›Paper›PMID 37432548›Full record

ReviewJournal of gastrointestinal cancer2024

The Role of Small Interfering RNAs in Hepatocellular Carcinoma.

Feng Chen, Wang Zhang, Xinran Gao, Hui Yuan, Kehai Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Feng ChenDepartment of Biopharmaceutical, Shanghai Ocean University, Shanghai, 201306, China.
Wang ZhangDepartment of Biopharmaceutical, Shanghai Ocean University, Shanghai, 201306, China.
Xinran GaoDepartment of Biopharmaceutical, Shanghai Ocean University, Shanghai, 201306, China.
Hui YuanDepartment of Biopharmaceutical, Shanghai Ocean University, Shanghai, 201306, China.
Kehai LiuDepartment of Biopharmaceutical, Shanghai Ocean University, Shanghai, 201306, China. khliu@shou.edu.cn.
Shanghai Ocean University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC), a primary liver cancer with high mortality, is the most common malignant tumor in the world. Currently, the effect of routine treatment is poor, especially for this kind of cancer with strong heterogeneity and late detection. In the past decades, the researches of gene therapy for HCC based on small interfering RNA have blossomed everywhere. This is a promising therapeutic strategy, but the application of siRNA is limited by the discovery of effective molecular targets and the delivery system targeting HCC. As the deepening of research, scientists have developed many effective delivery systems and found more new therapeutic targets.

conclusionsThis paper mainly reviews the research on HCC treatment based on siRNA in recent years, and summarizes and classifies the HCC treatment targets and siRNA delivery systems.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRNA, Small InterferingAnimalsGenetic TherapyHumansRNA, Small InterferingCancerGene therapyHepatocellular carcinomaSmall interfering RNA

Identifiers

PMID37432548
OpenAlexW4383873254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.